Tier 3 — preclinical

Association between blood nicotinamide adenine dinucleotide levels and blood laboratory parameters at baseline and after nicotinamide mononucleotide supplementation in middle-aged healthy individuals: post hoc analysis of a randomized, double-blinded, placebo-controlled clinical trial

Ajla H Kuerec, Weilan Wang, Keona D M Fokke, Lin Yi, Zhigang Lin, Aditi Vaidya, Sohal Pendse, Sornaraja Thasma, Niranjan Andhalkar, Ganesh Avhad, Vidyadhar Kumbhar, Andrea B Maier
GeroScience 2026 48(3):3305-3313

Bibliography

PubMed
PMID 41162813
PubMed Central
PMC13355995
DOI
10.1007/s11357-025-01968-0
Funding
This post-hoc analysis used the previously published 80-participant Yi NMN trial, which was funded by Aba Chemicals Co. and Abinopharm, Inc.
Competing interests
The parent trial included authors affiliated with Abinopharm and Aba Chemicals; this report should be interpreted in the context of the parent trial's industry funding.

Study snapshot

DesignPost-hoc analysis of the Yi randomized, double-blind, placebo-controlled dose-ranging trial.
ModelHealthy middle-aged adults aged 40–65 years from the Yi parent trial.
Samplen=80 parent-trial participants.
InterventionParent trial: placebo or NMN 300, 600 or 900 mg/day.
Duration60 days.
EndpointsBaseline blood NAD associations with hematologic, lipid and liver laboratory measures; Associations between NMN-induced NAD change and blood laboratory changes

What the study showed, in plain terms

This is a second post-hoc analysis of the 80-person Yi NMN trial, not a new clinical trial. It examined how blood NAD levels related to routine laboratory measurements before and after 60 days of supplementation.

Higher baseline NAD was associated with several blood-cell, lipid and liver markers, while larger NMN-related NAD increases were associated with modest increases in hemoglobin, red-cell measures and uric acid. Values generally remained within reference ranges, and the observational post-hoc design cannot establish that NAD changes caused those laboratory changes.

Key findings

  • The analysis reused the 80-person placebo/300/600/900 mg NMN parent trial.
  • Higher baseline NAD was associated with several inflammatory-cell, lipid and liver-laboratory measures.
  • Greater NAD increases after supplementation were associated with higher hemoglobin, RBC count, MCHC and uric acid.
  • The findings are associations and should not be counted as a separate randomized-trial efficacy result.

What this study can and cannot tell us

This was an exploratory post-hoc analysis with many laboratory associations and no new randomization. Associations may reflect individual metabolic setpoints or multiple testing rather than causal effects of NMN.

Related papers in the corpus

Tier 2
The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial
Lin Yi et al. · GeroScience · 2023
Tier 3
Towards personalized nicotinamide mononucleotide (NMN) supplementation: Nicotinamide adenine dinucleotide (NAD) concentration
Ajla Hodzic Kuerec et al. · Mechanisms of Ageing and Development · 2024

Citation network

Articles citing this research paper

2 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology